The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Role of Formulation Vehicles in Taxane Pharmacology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Self-citationEisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Central Nervous System Toxicity after Liver Transplantation
de Groen, P. C., Aksamit, A. J., Rakela, J., Forbes, G. S., & Krom, R. A. F. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710013171404 · Cited by 498
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., & Sartorius, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1692 · Cited by 426
Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind
Verweij, J., Clavel, M., & Chevalier, B. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058903 · Cited by 361
Self-citationSzebeni, J., Alving, C. R., & Muggia, F. M. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.4.300 · Cited by 341
(1999) · PubMed · Cited by 337
Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · PubMed · Cited by 313
Self-citationHuizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V, ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., & Beijnen, J. H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2127 · Cited by 308
Gianni, L., Viganò, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., & Bonadonna, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1906 · Cited by 278
Wiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., & Dutcher, J. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1232 · Cited by 275
Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
Gehl, J., Boesgaard, M., Paaske, T., Vittrup Jensen, B., & Dombernowsky, P. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010717 · Cited by 247
Reversal of multidrug resistance by surfactants
Woodcock, D., Linsenmeyer, M., Chojnowski, G., Kriegler, A., Nink, V, Webster, L., & Sawyer, W. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.217 · Cited by 233
Pharmacology and Toxicology of Cremophor EL Diluent
Dorr, R. T. (1994) · Annals of Pharmacotherapy · doi:10.1177/10600280940280s503 · Cited by 227
Lorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., & Doenicke, A. (1977) · Agents and Actions · doi:10.1007/bf01964882 · Cited by 219
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
Tellingen, O. V., Huizing, M. T., Panday, V. R. N., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690696 · Cited by 211
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Terwogt, J. M. M., Malingré, M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., & Schellens, J. H. M. (1999) · PubMed · Cited by 205
Drori, S., Eytan, G. D., & Assaraf, Y. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.1020m.x · Cited by 179
Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Chojnowski, G. M., Williams, B. T., & Bertoncello, I. (1990) · PubMed · Cited by 168
Holmes, F. A., Madden, T., Newman, R. A., Valero, V, Theriault, R. L., Fraschini, G., Walters, R. S., Booser, D. J., Buzdar, A. U., Willey, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2713 · Cited by 164
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
Adams, J. D., Flora, K. P., Goldspiel, B. R., Wilson, J., Arbuck, S. G., & Finley, R. W. (1993) · PubMed · Cited by 157
Sinicrope, F. A., Dudeja, P. K., Bissonnette, B. M., Safa, A. R., & Brasitus, T. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)73996-9 · Cited by 153
Reversal of Multidrug-Resistance Phenotype by Surfactants: Relationship to Membrane Lipid Fluidity
Dudeja, P. K., Anderson, K. M., Harris, J. S., Buckingham, L. E., & Coon, J. S. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1298 · Cited by 143
Ohtsu, T., Sasaki, Y., Tamura, T., et al. (1995) · PubMed · Cited by 143
Tissue distribution, metabolism and excretion of paclitaxel in mice
Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199601000-00009 · Cited by 128
Self-citationWebster, L. K., Linsenmeyer, M. E., Millward, M., Morton, C. G., Bishop, J. F., & Woodcock, D. M. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.20.1685 · Cited by 128
Paclitaxel pharmacokinetics and pharmacodynamics.
Kearns, C. M., Gianni, L., & Egorin, M. J. (1995) · PubMed · Cited by 126
van Tellingen, O., Beijnen, J. H., Verweij, J., Scherrenburg, E. J., Nooijen, W. J., & Sparreboom, A. (1999) · PubMed · Cited by 113
Self-citationSuccessful parenteral desensitization to paclitaxel
Essayan, D. M., Kagey‐Sobotka, A., Colarusso, P., Lichtenstein, L. M., Ozols, R. F., & King, E. D. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70281-6 · Cited by 109
Potential neurotoxicity of the solvent vehicle for cyclosporine.
Windebank, A. J., Blexrud, M. D., & de Groen, P. C. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38962-7 · Cited by 105
Liebmann, J., Cook, J. A., Lipschultz, C. A., Teague, D., Fisher, J. M., & Mitchell, J. B. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685909 · Cited by 102
Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro
Terzis, A., Thorsen, F., Heese, O., Visted, T., Bjerkvig, R., Dahl, O., Arnold, H., & Gundersen, G. G. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.298 · Cited by 100
Clinical relevance of P-glycoprotein expression in haematological malignancies
Nooter, K., & Sonneveld, P. (1994) · Leukemia Research · doi:10.1016/0145-2126(94)90025-6 · Cited by 95
Onetto-Pothier, N., Canetta, R. M., Winograd, B., Catane, R., Dougan, M., Grechko, J., Burroughs, J., & Rozencweig, M. (1993) · PubMed · Cited by 92
Cremophor EL, solvent for paclitaxel, and toxicity
Liebmann, J., Cook, J., & Mitchell, J. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)92789-v · Cited by 85
Sparreboom, A., Verweij, J., van der Burg, M. E. L., Loos, W. J., Brouwer, E., Viganò, L., Locatelli, A., de Vos, A. I., Nooter, K., Stoter, G., et al. (1998) · PubMed · Cited by 82
Self-citationIs Cremophor EL, solvent for paclitaxel, cytotoxic?
Fjällskog, M.-L., Frii, L., & Bergh, J. C. S. (1993) · The Lancet · doi:10.1016/0140-6736(93)92735-c · Cited by 76
Contact allergenic activity of Tween® 80 before and after air exposure
Bergh, M., Magnusson, K., Nilsson, J., & Karlberg, A. (1997) · Contact Dermatitis · doi:10.1111/j.1600-0536.1997.tb00368.x · Cited by 71
Effects of Cremophor EL on distribution of Taxol to serum lipoproteins
Sykes, E., Woodburn, K. W., Decker, D., & Kessel, D. H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.317 · Cited by 69
Azmin, M. N., Stuart, J. F. B., & Florence, A. T. (1985) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00258124 · Cited by 69
Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80
Ellis, A. G., Crinis, N. A., & Webster, L. K. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050451 · Cited by 66
Webster, L., Cosson, E., Stokes, K. H., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.90 · Cited by 65
van Zuylen, L., Gianni, L., Verweij, J., Mross, K. B., Brouwer, E., Loos, W. J., & Sparreboom, A. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200006000-00003 · Cited by 64
Self-citationThe polyoxyethylene castor oil Cremophor EL modifies multidrug resistance
Schuurhuis, G. J., Broxterman, H. J., Pinedo, H. M., van Heijningen, T. H. M., van Kalken, C. K., Vermorken, J. B., Spoelstra, E. C., & Lankelma, J. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.335 · Cited by 63
Paclitaxel in Cancer Treatment
Kaye, S. B. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.72 · Cited by 63
Quantitation of Cremophor EL in Human Plasma Samples Using a Colorimetric Dye-Binding Microassay
Sparreboom, A., Loos, W. J., Verweij, J., de Vos, A. I., van der Burg, M. E. L., Stoter, G., & Nooter, K. (1998) · Analytical Biochemistry · doi:10.1006/abio.1997.2467 · Cited by 53
Self-citationHypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel
Panday, V. R. N., Huizing, M. T., Huinink, W. W. T. B., Vermorken, J. B., & Beijnen, J. H. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199714050-00011 · Cited by 52
PROPERTIES OF CREMOPHOR EL MICELLES PROBED BY FLUORESCENCE
Kessel, D. H. (1992) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1992.tb02187.x · Cited by 49
Lesser, G. J., Grossman, S. A., Eller, S., & Rowinsky, E. K. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685646 · Cited by 48
EFFECTS OF CYCLOSPORINE ON THE ISOLATED PERFUSED RAT KIDNEY
Luke, D. R., Kasiske, B. L., Matzke, G. R., Awni, W. M., & Keane, W. F. (1987) · Transplantation · doi:10.1097/00007890-198706000-00004 · Cited by 43
Brat, D. J., Aj, W., & Brimijoin, S. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11107-5 · Cited by 38
Phase I trial of cremophor EL with bolus doxorubicin.
Millward, M., Webster, L., Rischin, D., Stokes, K. H., Toner, G. C., Bishop, J. F., Olver, I., Linahan, B. Μ., Linsenmeyer, M. E., & Woodcock, D. M. (1998) · PubMed · Cited by 37
Pharmacokinetics of the Taxanes
Kearns, C. M. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03812.x · Cited by 35
Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL
Ellis, A. G., & Webster, L. K. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050857 · Cited by 33
Brouwer, E., Verweij, J., Hauns, B., Loos, W. J., Nooter, K., Mross, K. B., Stoter, G., & Sparreboom, A. (1998) · Analytical Biochemistry · doi:10.1006/abio.1998.2746 · Cited by 31
Self-citationPharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin
Colombo, T., Parisi, I., Zucchetti, M., Sessa, C., Goldhirsch, A., & D’lncalci, M. (1999) · Annals of Oncology · doi:10.1023/a:1008309916974 · Cited by 31
Fjällskog, M.-L., Frii, L., & Bergh, J. C. S. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90546-0 · Cited by 30
Kessel, D. H., Woodburn, K. W., Decker, D., & Sykes, E. (1995) · PubMed · Cited by 29
Disposition of [G-3H]paclitaxel and Cremophor EL in a Patient with Severely Impaired Renal Function
Gelderblom, H. A. J., Verweij, J., Brouwer, E., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14932-x · Cited by 25
Self-citationCs�ka, K., Dhar, S., Fridborg, H., Larsson, R., & Nygren, P. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970315)79:6<1225::aid-cncr23>3.0.co;2-0 · Cited by 24
Antiproliferative effects of paclitaxel (Taxol®) on human renal clear cell carcinomas in vitro
Reinecke, P., Corvin, J., Gabbert, H. E., & Gerharz, C. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00069-5 · Cited by 22
Duska, L., Penson, R. T., Supko, J. G., Finkelstein, D. M., Makastorsis, T., Gallagher, J., Borden, K., Goodman, A., Fuller, A. F., Nikrui, N., et al. (1999) · PubMed · Cited by 17
Hortobágyi, G. N., Willey, J. S., Rahman, Z. A., Holmes, F. A., Theriault, R. L., & Buzdar, A. U. (1997) · PubMed · Cited by 17
The pharmacokinetics of epirubicin and docetaxel in combination in rats
Sandström, M., Friberg, L. E., Freijs, A., & Karlsson, M. O. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051120 · Cited by 14
Thio TEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80
Masters, J. R., McDermott, B. J., Jenkins, W. E. A., Fenwick, E., Shah, P. J. R., Mundy, A. R., Loadman, P. M., & Bibby, M. C. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684884 · Cited by 13
Cited by
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Self-citationStrategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Metadata
- Authors
- van Zuylen, L., Verweij, J., & Sparreboom, A.
- Venue
- Investigational New Drugs
- Published
- 2001-05
- Volume
- 19
- Issue
- 2
- Pages
- 125-141
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W1583373908
- Cited by
- 293
- References
- 70
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.